[{"bbox": [91, 100, 368, 130], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [91, 202, 552, 234], "category": "Section-header", "text": "**Outstanding Convertible Instruments:**"}, {"bbox": [91, 266, 1509, 298], "category": "Text", "text": "Our Company does not have any outstanding convertible instruments as on the date of filing this Draft Red Herring Prospectus."}, {"bbox": [91, 330, 578, 362], "category": "Section-header", "text": "**Stock Market Data of the Equity Shares:**"}, {"bbox": [91, 394, 1561, 458], "category": "Text", "text": "Our Company is an \"Unlisted Issuer\" in terms of the SEBI (ICDR) Regulations, and this Issue is an \"Initial Public Offering\" in terms of the SEBI (ICDR) Regulations. Thus, there is no stock market data available for the Equity Shares of our Company."}, {"bbox": [91, 490, 680, 520], "category": "Section-header", "text": "**Mechanism for Redressal of Investor Grievances:**"}, {"bbox": [91, 553, 1561, 650], "category": "Text", "text": "The agreement between the Registrar to the Issue and our Company provides for retention of records with the Registrar to the Issue for a period of at least three (3) years from the last date of dispatch of the letters of allotment and demat credit to enable the investors to approach the Registrar to the Issue for redressal of their grievances."}, {"bbox": [91, 682, 1561, 778], "category": "Text", "text": "We hereby confirm that there are no investor complaints received during the three years preceding the filing of this Draft Red Herring Prospectus. Since there is no investor complaints received, none are pending as on the date of filing of this Draft Red Herring Prospectus."}, {"bbox": [91, 810, 1561, 1096], "category": "Text", "text": "Investors may contact the BRLMs for any complaint pertaining to the Issue. All grievances, may be addressed to the Registrar to the Issue, with a copy to the relevant Designated Intermediary, where the Application Form was submitted, quoting the full name of the sole or first Applicant, Application Form number, Applicants' DP ID, Client ID, PAN, address of the Applicant, number of Equity Shares applied for, date of Application Form, name and address of the relevant Designated Intermediary, where the Bid was submitted and ASBA Account number in which the amount equivalent to the Bid Amount was blocked. Further, the Applicant shall enclose the Acknowledgement Slip or provide the acknowledgement number received from the Designated Intermediaries in addition to the documents/information mentioned hereinabove. Our Company, BRLMs and the Registrar accept no responsibility for errors, omissions, commission of any acts of the Designated Intermediaries, including any defaults in complying with its obligations under the SEBI ICDR Regulations."}, {"bbox": [91, 1128, 686, 1161], "category": "Section-header", "text": "**Disposal of Investor Grievances by our Company:**"}, {"bbox": [91, 1193, 1561, 1289], "category": "Text", "text": "Our Company estimates that the average time required by our Company or the Registrar to the Issue for the redressal of routine investor grievances shall be fifteen (15) Working Days from the date of receipt of the complaint. In case of complaints that are not routine or where external agencies are involved, our Company will seek to redress these complaints as expeditiously as possible."}, {"bbox": [91, 1321, 1561, 1385], "category": "Text", "text": "Our Company has appointed Akhand Pratap Singh as a Company Secretary and the Compliance Officer to redress complaints, if any, of the investors participating in the Issue. Contact details for our Company Secretary and Compliance Officer are as follows:"}, {"bbox": [91, 1417, 572, 1480], "category": "Text", "text": "Akhand Pratap Singh\nCompany Secretary & Compliance Officer"}, {"bbox": [91, 1482, 1006, 1574], "category": "Text", "text": "**Q-Line Biotech Limited**\n298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station,\nLucknow, Uttar Pradesh, India, 226012"}, {"bbox": [91, 1576, 565, 1672], "category": "Text", "text": "**Tel.:** +91 522-2435570\n**E-mail:** Akhand.singh@qlinebiotech.com\n**Website:** www.qlinebiotech.com"}, {"bbox": [91, 1704, 1561, 1769], "category": "Text", "text": "Investors can contact the Compliance Officer or the Registrar in case of any pre-Issue or post-Issue related problems such as non-receipt of letters of allocation, credit of allotted Equity Shares in the respective beneficiary account etc."}, {"bbox": [91, 1800, 1561, 1896], "category": "Text", "text": "Pursuant to the press release no. PR. No. 85/2011 dated June 8, 2011, SEBI has launched a centralized web-based complaints redress system \"SCORES\". This would enable investors to lodge and follow up their complaints and track the status of redressal of such complaints from anywhere. For more details, investors are requested to visit the website www.scores.gov.in"}, {"bbox": [91, 1928, 1561, 1991], "category": "Text", "text": "Our Board by a resolution on September 27, 2025 constituted a Stakeholders Relationship Committee. For further details, please refer to section titled \"Our Management\" beginning on page 155 of this Draft Red Herring Prospectus."}, {"bbox": [91, 2023, 457, 2056], "category": "Section-header", "text": "**Status of Investor Complaints:**"}, {"bbox": [91, 2088, 1561, 2152], "category": "Text", "text": "We confirm that we have not received any investor complaint during the three years preceding the date of this Draft Red Herring Prospectus and hence there are no pending investor complaints as on the date of this Draft Red Herring Prospectus."}]